EE248 Cost Effectiveness of Novel Antiobiotic Imipenem/Cilastatin/Relebactam in Gram Negative Infections in Greece
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.496
https://www.valueinhealthjournal.com/article/S1098-3015(22)02700-0/fulltext
Title :
EE248 Cost Effectiveness of Novel Antiobiotic Imipenem/Cilastatin/Relebactam in Gram Negative Infections in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02700-0&doi=10.1016/j.jval.2022.09.496
First page :
Section Title :
Open access? :
No
Section Order :
10025